Anita Johnson, MD
Surgical Oncology · Woodstock, GANPI 1457401630
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $12,740 of the $18,478 with a category attached, or 68.9%. Merck accounts for 92.0% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2023 at $8,942 and has fallen 99.8% since, to $18 in 2025. Among surgical oncology clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 59 payments — averaging $313.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$17K
- Stryker$500
- Astellas Pharma US Inc$221
- Amgen$138
- Cardiva Medical, Inc.$132
- Kerecis Limited$99
- plus $387 from 16 others
What the payments were for
- Speaking & faculty fees$12,74069%
- Travel & lodging$4,39224%
- Food & beverage$1,3467%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 20 | $17,001 |
| Stryker | 2 | $500 |
| Astellas Pharma US Inc | 1 | $221 |
| Amgen | 10 | $138 |
| Cardiva Medical, Inc. | 1 | $132 |
| Kerecis Limited | 1 | $99 |
| Novartis | 4 | $52 |
| Gilead | 1 | $49 |
| Ipsen Biopharmaceuticals, Inc | 3 | $39 |
| Solventum Corporation | 1 | $30 |
| Bayer | 2 | $29 |
| Eisai Inc. | 2 | $22 |
| Acacia Pharma Inc | 1 | $22 |
| Elucent Medical | 2 | $21 |
| Daiichi Sankyo Inc. | 1 | $20 |
| GSK | 1 | $18 |
| Lexicon Pharmaceuticals, Inc. | 1 | $16 |
| Genentech USA, Inc. | 1 | $16 |
| Johnson & Johnson | 1 | $15 |
| Bristol Myers Squibb | 1 | $13 |
| Coherus Oncology, Inc. | 1 | $12 |
| Deciphera Pharmaceuticals Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KEYTRUDA$16,690
- 1688$488
- Cardiva VASCADE 6/7F VCS$132
How this compares
$18,478 in reported general payments places this provider in the 95th percentile of 43 surgical oncology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 22 | $122 |
Paid to pharmacies, not to this prescriber.
Other surgical oncology in Woodstock
- Eddie AbdallaAtlanta$34K
- Atuhani BurnettAtlanta$23K
- Danny YakoubAugusta$17K
- Nicole KounalakisAtlanta$14K
- Sartaj SangheraMarietta$10K
- Barry RosemanAtlanta$10K
- Arnold ConfortiMacon$9K
- James GarberSavannah$7K
- James GriffinAthens$7K
- David KoobyAtlanta$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.